Corporate News

2024

Posting of Annual Report and Notice of Annual General Meeting

05 June 2024

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer, confirms that the Annual Report and Accounts for the year ended 31 December 2023 and the Notice of Annual General Meeting (“AGM”) have been posted to shareholders.

A copy of the 2023 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy is now available to download from the Company website in accordance with AIM Rule 20: investors.genincode.com/investors

The AGM will be held in person at the offices of Cavendish Capital Markets, One Bartholomew Close, London, EC1A 7BL on Thursday 27 June 2024 at 2.00 p.m.

 

For more information visit www.genincode.com

 

Enquiries:

 

GENinCode Plc www.genincode.com or via Walbrook PR
Matthew Walls, CEO  
Paul Foulger, CFO
 
Cavendish Capital Markets Limited
 
Tel: +44 (0)20 7397 8900
Giles Balleny / Dan Hodkinson (Corporate Finance)
Nigel Birks / Harriet Ward (Corporate Broking)
Dale Bellis / Michael Johnson (Sales)
 
Walbrook PR Limited
Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage
 
Tel: 020 7933 8780 or [email protected]  
   

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease and ovarian cancer. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.

GENinCode predictive technology provides patients and physicians with globally leading preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer.

2023

Posting of Annual Report and Notice of Annual General Meeting

05 June 2024

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer, confirms that the Annual Report and Accounts for the year ended 31 December 2023 and the Notice of Annual General Meeting (“AGM”) have been posted to shareholders.

A copy of the 2023 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy is now available to download from the Company website in accordance with AIM Rule 20: investors.genincode.com/investors

The AGM will be held in person at the offices of Cavendish Capital Markets, One Bartholomew Close, London, EC1A 7BL on Thursday 27 June 2024 at 2.00 p.m.

 

For more information visit www.genincode.com

 

Enquiries:

 

GENinCode Plc www.genincode.com or via Walbrook PR
Matthew Walls, CEO  
Paul Foulger, CFO
 
Cavendish Capital Markets Limited
 
Tel: +44 (0)20 7397 8900
Giles Balleny / Dan Hodkinson (Corporate Finance)
Nigel Birks / Harriet Ward (Corporate Broking)
Dale Bellis / Michael Johnson (Sales)
 
Walbrook PR Limited
Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage
 
Tel: 020 7933 8780 or [email protected]  
   

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease and ovarian cancer. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.

GENinCode predictive technology provides patients and physicians with globally leading preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer.

2022

Posting of Annual Report and Notice of Annual General Meeting

05 June 2024

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer, confirms that the Annual Report and Accounts for the year ended 31 December 2023 and the Notice of Annual General Meeting (“AGM”) have been posted to shareholders.

A copy of the 2023 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy is now available to download from the Company website in accordance with AIM Rule 20: investors.genincode.com/investors

The AGM will be held in person at the offices of Cavendish Capital Markets, One Bartholomew Close, London, EC1A 7BL on Thursday 27 June 2024 at 2.00 p.m.

 

For more information visit www.genincode.com

 

Enquiries:

 

GENinCode Plc www.genincode.com or via Walbrook PR
Matthew Walls, CEO  
Paul Foulger, CFO
 
Cavendish Capital Markets Limited
 
Tel: +44 (0)20 7397 8900
Giles Balleny / Dan Hodkinson (Corporate Finance)
Nigel Birks / Harriet Ward (Corporate Broking)
Dale Bellis / Michael Johnson (Sales)
 
Walbrook PR Limited
Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage
 
Tel: 020 7933 8780 or [email protected]  
   

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease and ovarian cancer. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.

GENinCode predictive technology provides patients and physicians with globally leading preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer.

2021

Posting of Annual Report and Notice of Annual General Meeting

05 June 2024

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer, confirms that the Annual Report and Accounts for the year ended 31 December 2023 and the Notice of Annual General Meeting (“AGM”) have been posted to shareholders.

A copy of the 2023 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy is now available to download from the Company website in accordance with AIM Rule 20: investors.genincode.com/investors

The AGM will be held in person at the offices of Cavendish Capital Markets, One Bartholomew Close, London, EC1A 7BL on Thursday 27 June 2024 at 2.00 p.m.

 

For more information visit www.genincode.com

 

Enquiries:

 

GENinCode Plc www.genincode.com or via Walbrook PR
Matthew Walls, CEO  
Paul Foulger, CFO
 
Cavendish Capital Markets Limited
 
Tel: +44 (0)20 7397 8900
Giles Balleny / Dan Hodkinson (Corporate Finance)
Nigel Birks / Harriet Ward (Corporate Broking)
Dale Bellis / Michael Johnson (Sales)
 
Walbrook PR Limited
Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage
 
Tel: 020 7933 8780 or [email protected]  
   

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease and ovarian cancer. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.

GENinCode predictive technology provides patients and physicians with globally leading preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer.